Gamida Cell surges following Phase 3 omidubicel study results announcement Check out this morning's top movers from around Wall Street, compiled by The Fly.
HIGHER -
- Gamida Cell (GMDA) up 41% after announcing the results of its Phase 3 study of omidubicel in patients with hematologic malignancies show that omidubicel resulted in faster hematopoietic recovery, fewer bacterial and viral infections and fewer days in hospital
- Atlas Crest Investment Corp. (ACIC) up 36% after
announcing Archer (ACHR) and the company have entered into a definitive agreement for a business combination that would result in Archer becoming a publicly listed company and that United Airlines (UAL) has entered into an agreement to invest in Archer
- CM Life Sciences (CMLF) up 48% after
Sema4 and the company announced they have entered into a definitive business combination agreement under which CM Life Sciences will be renamed and its common stock will be listed on the Nasdaq global market under a name and a ticker symbol to be announced at a later date
UP AFTER EARNINGS -
- Coca-Cola (KO) up 2%
- Iqvia (IQV) up 4%
- Lyft (LYFT) up 10%
DOWN AFTER EARNINGS -
- General Motors (GM) down 1%
- Cisco (CSCO) down 5%
- Akamai (AKAM) down 8%
LOWER -
- Cassava Sciences (SAVA) down 9% after announcing a $200M registered direct offering of common stock
- Enlivex Therapeutics (ENLV) down 13% after a 2.3M share spot secondary priced at $20.00
- ExOne (XONE) down 11% after a 1.667M share spot secondary priced at $54.00
Symbols:
GMDA ACIC CMLF KO GM IQV LYFT CSCO AKAM SAVA ENLV XONE ACHR UAL Keywords: Fly Intel, Wall Street, Top Stories, Stocks